− interleukin-10 (IL-10)-producing CD4 + T cells with potent immunosuppressive properties, but their requirements for lineage development have remained elusive. We show that T R 1 cells constitute the most abundant regulatory population after allogeneic bone marrow transplantation (BMT), express the transcription factor Eomesodermin (Eomes), and are critical for the prevention of graft-versus-host disease. We demonstrate that Eomes is required for T R 1 cell differentiation, during which it acts in concert with the transcription factor B lymphocyte-induced maturation protein-1 (Blimp-1) by transcriptionally activating IL-10 expression and repressing differentiation into other T helper cell lineages. We further show that Eomes induction in T R 1 cells requires T-bet and donor macrophage-derived IL-27. Thus, we define the cellular and transcriptional control of T R 1 cell differentiation during BMT, opening new avenues to therapeutic manipulation.
INTRODUCTION

Type 1 regulatory T (T R 1) cells are a FoxP3
− , interleukin-10 (IL-10)-producing T cell population, which have potent immunosuppressive functions and bear alloantigen specificity (1, 2) . IL-10 is the major mediator by which T R 1 cells assert their immunomodulatory role. Direct and bystander-mediated T cell suppression by transforming growth factor- (TGF-) and granzyme B (GzmB)-dependent killing of antigen-presenting cells (APCs) have also been described [reviewed in (3) ]. In addition to IL-10, T R 1 cells show high expression of TGF- and secrete intermediate amounts of interferon- (IFN) but not IL-2 or IL-4 (3) (4) (5) . Extensive studies have demonstrated the importance of T R 1 cells in maintaining immune tolerance or limiting overt inflammation after transplantation, during autoimmune disease, or after infections (6) (7) (8) (9) . IL-27 has been identified as a main driver of T R 1 cell differentiation via the activation of transcription factors that include B lymphocyte-induced maturation protein-1 (Blimp-1), the aryl hydrocarbon receptor (AhR), and c-Maf (5) (6) (7) (8) (10) (11) (12) . However, the function, phenotype, and lineage development of T R 1 cells in disease states remain poorly understood (5, 13) .
Graft-versus-host disease (GVHD) is a common complication of allogeneic bone marrow transplantation (BMT), limiting survival and quality of life (14) . CD4 +
FoxP3
+ regulatory T (T reg ) cells are a welldefined regulatory population important for the generation of tolerance after BMT (15) . Because of impaired homeostasis of T reg cells after allogenenic BMT (16) , other suppressive cell populations such as T R 1 cells may be imperative for the prevention and treatment of GVHD. Consistent with this idea, IL-10 deficiency in donor T cells results in more severe GVHD (17, 18) . Thus, we developed a mouse model using a dual Il10 GFP /Foxp3 RFP reporter mouse strain (19, 20) to delineate T reg cell responses after experimental BMT. Using GVHD as a disease model, we show that T R 1 cells are the most abundant IL-10-producing T reg cell population after experimental BMT. Further analyses demonstrate that T R 1 cells that develop during GVHD express high amounts of Eomesodermin (Eomes), which is required for their development, and its overexpression promotes T R 1 cell development both in vivo and in vitro. Eomes acts in concert with Blimp-1, a known transcriptional regulator of T R 1 cell differentiation (6) (7) (8) 21) , to induce IL-10 expression. We further show that Eomes expression and T R 1 cell development require T-bet and donor macrophage-derived IL-27, resulting in a T-bet lo Eomes hi phenotype. Last, we demonstrate that Eomes + T R 1 cells are abundant after clinical BMT, indicating the applicability of our findings. Our findings open the way for new therapeutic strategies in transplantation and other clinical settings. 1A) . T cells were the major IL-10 producers after both allogeneic and syngeneic BMT (Fig. 1B) , with the highest proportion and intensity of IL-10 produced by T R 1 cells (Fig. 1C) . T R 1 cells were present at up to 10-fold higher frequency and number than T reg cells after allogeneic BMT in GVHD target tissues (liver and, to a lesser extent, small intestine), mesenteric lymph nodes (Fig. 1D) , and spleen ( Fig. 1, D to F) . T R 1 cells induced under these conditions had suppressive properties in vitro equivalent to posttransplant T reg cells on a per-cell basis (Fig. 1G and fig. S1 ). To confirm their suppressive function in vivo, we induced GVHD with wild-type (WT) or Il10 −/− CD4 + CD25 − T cells that cannot develop into functional T R 1 cells. As expected, we observed enhanced GVHD in the absence of IL-10; however, adoptive transfer of limited numbers of T R 1 cells at day 7 after BMT ( Fig. 1H) , when acute GVHD was established, prolonged survival significantly (Fig. 1I) , consistent with potent regulatory function. Thus, T R 1 cells represent the major T reg cell population in GVHD induced by allogeneic BMT and contribute significantly to transplant survival.
RESULTS
T R 1 cells represent a major T reg cell population in GVHD
T R 1 cells express Eomes and display a distinct phenotypic profile
CD49b and LAG-3 coexpression can be used to identify T R 1 cells in models of colitis (9); however, their expression is insufficient to identify T R 1 cells after BMT ( fig. S2A ). Therefore, we used Foxp3
RFP− and Il10
GFP+ as T R 1 cell markers. Thus defined T R 1 cells demonstrated high expression of CD122, 47, LAG-3, Ly6C, and TIGIT and low expression of CD25 and CD69 relative to other CD4 + T cell subsets ( fig. S2B ). Consistent with the T R 1 cell phenotype (3, 5, 9) , Foxp3
RFP−
Il10
GFP+ T R 1 cells expressed high amounts of IL-10 and IFN but little T helper 2 (T H 2) cytokines, such as IL-4, IL-13, and IL-5, or T H 17 cytokines, such as IL-17, IL-6, or granulocyte-macrophage colony-stimulating factor (GM-CSF) ( Fig. 2A and fig. S2C ).
T R 1 cells have often been considered a terminally differentiated T H 1 cell subset programmed to limit aberrant inflammation (5, 13, 22) . T R 1 cells expressed high amounts of T-bet, the T H 1 cell-determining transcription factor, but low amounts of GATA-3, BCL-6, and RORt. When we analyzed the expression of other transcription factors related 
to T cell differentiation, we observed high Eomes expression, which was largely restricted to T R 1 cells (Fig. 2B and fig. S2D ). Eomes expression tightly correlated with high expression of IL-10, IFN, and GzmB (Fig. 2C ). In contrast, Eomes + T R 1 cells expressed low levels of IL-2, IL-17A, and GM-CSF (Fig. 2C) . Thus, T R 1 cells that develop during allogeneic BMT specifically express Eomes.
Eomes is required for T R 1 cell differentiation
To test the role of Eomes in T R 1 cell development in vivo, we used CD4 + T cells isolated from Eomes fl/f l ×Cd4-cre donor mice in allogeneic BMT. Strikingly, T R 1 cell generation was significantly reduced (by >70%) with decreased GzmB expression in recipients of Eomes-deficient CD4 + T cells (Fig. 3A and fig. S3, A (Fig. 3A and fig. S3 (Fig. 3B ). In addition, overexpression of Eomes promoted the expression of GzmB while suppressing FoxP3, IL-4, and IL-17A expression ( fig. S3G ). Furthermore, overexpression of Eomes up-regulated the transcription of Il10 but suppressed that of other lineage-defining transcription factors including Tbx21, Gata3, Rorc, Bcl6, and Foxp3, in addition to the T R 1/T H 17 cell-related factors Ahr and Il21 (Fig. 3C) (10, 23, 24) . T R 1 cells generated in vitro in the presence of IL-27, a cytokinepromoting T R 1 cell development (8, 11, 12) , did not express Eomes protein, nor did T H 1, T H 2, T H 17, and induced T reg cells ( fig. S4A ), indicating that short-term in vitro cultures do not replicate the conditions inducing T R 1 cells after BMT. Nevertheless, Eomes mRNA was higher in T R 1 cell than in other T cell lineages in these cultures ( fig. S4B ). Consistent with this observation, we did not observe a defect in T R 1 cell differentiation in the absence of Eomes in these conditions ( fig. S5A) fig. S5C ). Collectively, we show that Eomes is required for T R 1 cell differentiation, IL-10 secretion, and repression of alternative fate differentiation.
Eomes directly regulates IL-10 expression in T R 1 cells
To understand the mechanism by which Eomes regulates T R 1 cell differentiation, we performed chromatin immunoprecipitation (ChIP) assays on sort-purified T R 1 cells or CD4 + T cells 14 days after BMT. This demonstrated that Eomes is bound to multiple sites within 2 kb upstream of the transcription start site (TSS) of the Il10 gene (Fig. 3D) . The binding of Eomes to the Il10 promoter was similar to that observed in the Ifn promoter, suggesting that Eomes regulates expression of both Il10 and Ifn directly. Consistent with this concept, the recruitment of RNA polymerase II to the Il10 promoter, an indicator of transcriptional activity, was reduced in Eomes-deficient CD4 + T cells (Fig. 3D ).
Eomes + T R 1 cells are dependent on Blimp-1, IL-27, and IL-10
Blimp-1 is a well-defined transcriptional promoter of IL-10 in CD4 + T con and T reg cells (6, 11, 21) . Consistent with this notion, after BMT, IL-10 production in all CD4 by >80% (Fig. 4D and fig. S6E ). In contrast, T-bet expression was increased in the absence of IL-27 signaling ( We next tested whether the differentiation of Eomes + T R 1 cells was dependent on IL-10 itself. The expression of Eomes, T R 1 cells, and T-bet was not reduced in Il10r-deficient CD4 + T cells (Il10r fl/f l ×Lck-cre) after BMT (Fig. 4E and fig. S6F ), indicating that IL-10 signaling in T cells was not required for T R 1 cell differentiation. However, when we transplanted Il10 −/− CD4 + CD25 − T cells, Eomes + cells were reduced (Fig. 4F ), in line with the notion that IL-10 promotes T R 1 cell differentiation indirectly (22, 25) . In summary, Eomes expression in T R 1 cells is downstream of IL-27 and Blimp-1 but does not depend on T cellintrinsic IL-10 signaling.
Eomes
+ T R 1 cells are critical for the prevention of GVHD We next examined whether Blimp-1-and Il27r-deficient CD4 + T cells would exacerbate GVHD due to impaired expression of Eomes and T R 1 cells. Whereas Blimp-1 deletion exacerbated GVHD (Fig. 5A) , IL-27 receptor (IL-27R) deletion did not (Fig. 5B) . Notably, T reg cells were increased, and their IL-10 production was intact in recipients of Il27r −/− CD4 + T cells (figs. S6E and S7A), consistent with compensatory regulatory pathways in the absence of T R 1 cells. In contrast, Il10 −/− CD4 + T cells sustain comparable expression of Eomes in T con and T reg cells (Fig. 4F and fig. S7B ) after BMT and thus reflect a more relevant model to define the regulatory function of T R 1 cells in vivo. Consistent with the reduced frequency of T R 1 cells, we observed enhanced GVHD in the skin and liver in recipients of Il10 −/− CD4 + CD25 − T cells (Fig. 5C ). These findings were confirmed by transplanting Il10 fl/fl ×Lck-cre CD4 + CD25 − T cells, which also led to exacerbated GVHD in the absence of IL-10-producing T R 1 cells (Fig. 5D) . Last,
− T cells also resulted in increased GVHD, further confirming the important regulatory role of Eomes + T R 1 cells after BMT (Fig. 5E ).
Eomes and T-bet cooperate to generate T R 1 cells
As we had observed coexpression of T-bet (encoded by Tbx21) and Eomes in T R 1 cells after BMT, we wished to test the role of IFN signaling and T-bet in T R 1 cell development. Transplanting Ifngr −/− donor T cells or neutralizing IFN resulted in reduced expression of T-bet and Eomes (Fig. 6A) , with reduced expression of Eomes + T R 1 cells and expanded T reg cell populations (Fig. 6 , B and C). When we transplanted Tbx21 −/− CD4 + T cells during BMT, we found that Eomes + T R 1 cells were markedly reduced (Fig. 6D and fig. S8A ). Although overall frequencies of IL-10
+ T cells were unaffected, the absolute numbers were reduced (Fig. 6D) . However, most of the Tbx21 −/− IL-10 + CD4 + T cells did not express IFN but rather IL-4 and GATA3 or IL-17A, indicating that these cells had been diverted to T H 2 or T H 17 cells, respectively ( Fig. 6D and fig. S8B ). Gene expression analysis confirmed polarization of donor CD4 + T cells to T H 2 (Gata3, Il4, and Il13) and T H 17 (Rorc, Ahr, and Il21) cell lineages in the absence of T-bet. The transcription of Il10 (from T H 2 cells) was also increased (fig. S8C) (Fig. 6E and  fig. S8, E and F) . We next investigated whether there is a temporal and/or spatial collaboration between T-bet and Eomes during T R 1 cell development. (Fig. 6F) , correlating with the increasing frequency of T R 1 cells (Fig. 1E) . Furthermore, after repeated exposure to high levels of alloantigen in vivo, most donor CD4 + T cells had acquired Eomes (>95%) and converted to T R 1 cells (>70%) within 4 weeks of transfer into secondary BMT recipients ( fig. S8H ). Consistently, overexpression of Eomes suppressed the expression of T-bet while promoting T R 1 cell differentiation (Fig. 3B and fig. S8I ). (Fig. 6G) . Collectively, these data show that both T-bet and Eomes are required for T R 1 cell differentiation, which is characterized by the initial up-regulation of T-bet, the acquisition of Eomes expression, and the subsequent down-regulation of T-bet, resulting in a T-bet lo Eomes hi phenotype.
Recipient DC and donor-derived IL-27 promote T R 1 cell development GVHD is initiated by recipient APCs and is influenced by the intensity of conditioning, that is, total body irradiation (TBI) and chemotherapy dose intensity, in part through inflammatory cytokine dysregulation (26, 27) . Thus, we hypothesized that T R 1 cells may also be generated in an APC-and conditioning-dependent fashion. The frequency of T R 1 cells in donor CD4 + T cells correlated with the frequency of residual recipient conventional dendritic cells (DCs) (Fig. 7A) and reduced intensity of TBI that favors the persistence of recipient DC ( fig. S9A ). Blocking DC function by CD40L inhibition reduced T R 1 cells while favoring T reg cell development (Fig. 7B ). In line with this observation, depletion of both donor and recipient DC markedly reduced the development of T R 1 cells early after BMT (Fig. 7C) . Whereas the proportions of T reg cells were unaffected, absolute numbers were reduced, albeit much less markedly than T R 1 cells (Fig. 7C) . In contrast, the depletion of donor DC or inactivation of donor APC function in isolation did not impair T R 1 cell development (Fig. 7D and fig. S9 , B and C),
indicating that recipient DCs are required for the development of T R 1 cells early after BMT. Consistent with the notion that Eomes + T R 1 cells are dependent on IL-27 signaling and further confirming critical role of IL-27 in promoting T R 1 cell development, we found that the number of T R 1 cells significantly correlated with the number of IL-27 + cells in the spleen (Fig. 7E) . Because IL-27R and IL-6R share and compete for the same signaling component, gp130 (28), we hypothesized that blocking IL-6R may favor IL-27R function. As expected, IL-6R inhibition blocked signal transducer and activator of transcription 3 (STAT3) phosphorylation in response to IL-6 but not IL-27 (Fig. 7F ). In contrast, IL-6R inhibition enhanced STAT1 phosphorylation in response to IL-27 early after BMT (Fig. 7F ) and resulted in increased expression of T R 1 cells and a small increase in the frequencies of T reg cells (Fig. 7G and fig. S9D ). The enhanced STAT1 phosphorylation in response to IL-27 after IL-6R inhibition was not a result of an increase in the number of cells producing IL-27 itself or IL-27 production on a per-cell basis (Fig. 7H) . We next sought to identify the cellular sources of IL-27 after BMT. Most IL-27 (70 to 80%) was produced by (Fig. 7I) . More than 80% of all Ly6C hi donor macrophages were secreting IL-27 after BMT (Fig. 7J) . Depletion of donor DC did not impair the overall frequencies or numbers of IL-27 + cells ( fig. S9B) , consistent with the lack of contribution by donor DC to T R 1 cell development. Last, we demonstrated that recipient DC did not produce IL-27 early after BMT (Fig. 7K) , suggesting that the requirement of recipient DC to T R 1 cell development relates to their capacity for alloantigen presentation and not IL-27 production. Thus, donor macrophages appear as the main producers of IL-27 and, in concert with the initial stimulation by recipient DC, drive Eomesdependent T R 1 development after BMT.
To further understand the requirement of Eomes in T R 1 cell development, we investigated the expression of Eomes + T R 1 cells in other models of immunopathology. To this end, we used Foxp3 GFP-DTR mice to temporarily deplete T reg cells, thereby causing autoimmunity (29) (30) (31) . Depletion of T reg cells from adult mice resulted in a marked increase in IL-27-producing Ly6C hi macrophages (Fig. 7L ) and, critically, induced large numbers of Eomes + T R 1 cells (Fig. 7M) . Thus, our data show that different inflammatory conditions result in the development of Eomes + T R 1 cells. Furthermore, our results demonstrated that defects in T reg cells are associated with compensatory increases in Eomes + T R 1 cells.
Identification of T R 1 cells in humans
To validate whether our findings from experimental BMT can be translated into humans, we analyzed the expression of Eomes, IL-10, and other markers in CD4 + T lymphocytes collected from healthy donors and BMT recipients. Eomes ) provides better discrimination of T R 1 cells between healthy donors and BMT recipients (Fig. 8B) . Furthermore, the (Fig. 8, C to E,  and fig. S10 ). Thus, consistent with the findings in the mouse model, after clinical BMT, high Eomes and low T-bet expression in CD4 + T cells can be used to identify a population that is enriched for T R 1 cells.
DISCUSSION
We demonstrate that Eomes acts together with Blimp-1 and specifically drives the development of T R 1 cells. On the basis of our data and published results (8, 32) , we propose a model for the differentiation of T R 1 cells after BMT, as illustrated in fig. S11 . In this model, antigen presentation by recipient DC and macrophage-derived IL-27 provide the cellular and molecular cues for the development of T R 1 cells, inducing Blimp-1 expression, which initiates the transcription of Il10. Blimp-1 is also required for Eomes expression, and both factors act in concert, enabling stable IL-10 production and T R 1 cell differentiation. Concurrently, T-bet is required to suppress GATA3 and RORt while driving IFN and Eomes expression, ultimately leading to a T-bet lo Eomes hi phenotype, which can reliably identify T R 1 cells after BMT as well as in steady state in mouse and man. There are some limitations to this study. Our preclinical studies used predominantly a single transplant model, although clinical data were congruent. In addition, although T reg cell depletion results in T R 1 cell generation in vivo, it is not yet clear how important T R 1 cells are in other disease settings. Last, the relative in vivo suppressive activity of T R 1 cells versus T reg cells remains to be explored.
There is still debate whether T R 1 cells constitute an independent lineage or simply represent IL-10-producing T H 1 cells. In particular, the lack of a master transcriptional factor for T R 1 cells has made progression of the field difficult (5, 13, 33) . Multiple transcription factors, including Blimp-1, AhR, and c-Maf, are induced by IL-27 and have been shown to be critical for T R 1 cell differentiation (5) (6) (7) (8) 10) ; however, none of them appear to be specific to the T R 1 cell lineage. Eomes is a T-box transcription factor that is more often than not coupled with T-bet in the biology of CD8 + T cells and natural killer cells (34, 35) . Its role in regulating functions of CD4 + T cells (36, 37) and suppressing T reg and T H 17 cell differentiation have been described recently (38, 39) . Here, we demonstrate that IL-10 + IFN + T R 1 cells are uniquely dependent on Eomes. We found that Eomes bound to the Il10 and Ifn promoters. Similarly, it has been shown that Eomes also binds to the promoter of Gzmb (35) , the expression of which is another feature of T R 1 cells. Eomes overexpression was sufficient to promote IL-10 and GzmB and suppress other lineage-characteristic transcription factors (e.g., FoxP3, GATA-3, RORt, and BCL-6) and cytokines (e.g., IL-2, IL-4, IL-13, GM-CSF, and IL-17A). Therefore, expression of Eomes and IL-10 within CD4 + T cells defines the T R 1 cell lineage. Increasing data have suggested a close relationship between T R 1 and T H 17 cells linked via AhR, c-Maf, and IL-21 (10, 23, 24, 40) . However, T R 1 and T H 17 cells require different cytokines for their respective differentiation: IL-27/IL-10 for the former and IL-6/TGF-/IL-23 for the latter (12, (41) (42) (43) . Multiple groups have independently shown that IL-27 opposed the functions of IL-6/IL-23 in T H 17 cell differentiation (8, 28, 44 (39) . A role for IL-27 in inhibiting T reg cell reconstitution after BMT has also recently been reported (45) , consistent with the counterbalanced T R 1 cell expansion seen here. There appears to be substantial interplay between IL-6 and IL-27 (28) , an effect also seen during GVHD. IL-6 inhibition has an intriguing capacity to enhance IL-27 responses and thereby to promote T R 1 cell differentiation, an effect likely contributing to clinical efficacy (46) . Eomes can be regulated by T-bet in a Runx-3-dependent manner, and the differential expression of these two T-box transcription factors is critical for the differentiation of CD8 + T cells (47, 48) . In line with this notion, we show that IFN signaling and T-bet expression were required for Eomes expression, demonstrating an important role of T-bet in the early phase of T R 1 cell development. Downstream of IL-27, Blimp-1 is critical for the expression of IL-10 in CD4 + T cells in various models (6-8, 21, 49) . Here, we show that Eomes + T R 1 cells were regulated by both Blimp-1 and T-bet, consistent with a recent report that demonstrated close collaboration between Blimp-1 and T-bet in cytotoxic T lymphocyte generation (50) . In addition, binding of Blimp-1 to the Eomes promoter in CD8 + T cells during viral infection has been described (32) , suggesting that Blimp-1 not only regulates IL-10 expression directly but also contributes to the induction or maintenance of Eomes expression in T R 1 cells. Both Blimp-1 (6) and Eomes bind to the Il10 locus, and the activity of both is required to promote efficient T R 1 cell differentiation and Il10 expression. Similar to Eomes, Blimp-1 is required not only for IL-10 expression but also for GzmB (51) . We also confirmed that IL-10 itself contributes to T R 1 cell differentiation, a T cell-extrinsic effect likely via myeloid cells (22, 25) . Overall, these data suggest that the functional interactions between Blimp-1, T-bet, and Eomes are important for the differentiation of CD4 + T cells and T R 1 cell lineage in particular. Identification of the bona fide transcriptional and cellular control of T R 1 cell development should allow for therapeutic utilization of T R 1 cells in transplantation and other diseases, where excessive and aberrant immunity results in immunopathology. 5′-tttggaacagcctccaaatc-3′ (reverse) were used to detect the wild-type (339 bp) and floxed allele (421 bp) while primer (e) 5′-AAGGGGAAGG-GTGGTTAGAA-3′ (reverse) was used to detect the floxed allele (1941 bp) and germline deletion (587 bp). This Eomes floxed line was subsequently crossed with Cd4-cre or Lck-cre mice to generate T cell-restricted Eomes −/− offspring. All recipient mice were used between 6 and 10 weeks of age, and age-matched female donor mice were used. Mice were housed in microisolator cages and received acidified autoclaved water (pH 2.5) after BMT. All animal studies were performed in accordance with the QIMR Berghofer Medical Research Institute Animal Ethics Committee. We chose sample sizes based on estimates from initial and previously published results to ensure appropriate power. As stated in the figure legends and wherever possible, n values were derived from individual mice from replicated experiments.
MATERIALS AND METHODS
Study design
Bone marrow transplantation BM (B6.CD45.1 + or where indicated) was T cell-depleted, and splenocytes were processed to CD3 + or CD4 + T cells, as described previously (56) . On day −1, recipient mice received 1100 centigray (cGy) (B6D2F1), 1000 cGy (B6), 900 cGy (CD11c-DOG×DBA/2 F1), or otherwise specified doses of TBI ( . Intraperitoneal injections of rat anti-mouse IFN (XMG1.2, produced in-house, 1 mg per dose, three times per week), hamster antimouse CD40L (MR1, BioXcell; 500 g per dose, days 0, +2, +4, and +6), rat anti-mouse IL-6R (MR16-1, Chugai Pharmaceutical Co., Japan; 500 g per dose, days −1, +3, and +7), and control monoclonal antibody (mAb) were administered to recipients. In some experiments, CD11c-DOG mice [in which diphtheria toxin (DT) receptor is driven off the CD11c promoter] were used as BM donors. Recipients were given intraperitoneal injections of DT (160 ng per dose, three times per week) after BMT to deplete donor DC. For depletion of recipient DC, B6.CD11c-DOG×DBA/2 F1 mice were used as recipients and treated with DT on days −3, −1, 0, +1, +3, +5, and +7.
T reg cell depletion
For depletion of T reg cells, age-matched recipients (B6.WT or B6. Foxp3 GFP-DTR ) were given intraperitoneal injections of DT (160 ng per dose, three times per week) for up to 2 weeks. Histology GVHD target tissues (skin, liver, and small intestine) were taken, preserved in 10% formalin, embedded in paraffin, processed to 5-mm-thick sections, and stained with hematoxylin and eosin. The sections were examined in a blinded fashion using a semiquantitative scoring system, and images were acquired as previously described (56, 57) .
Flow cytometry
Single-cell suspensions were processed and stained, cells were analyzed on an LSRFortessa cytometer (Becton Dickinson), and data were processed using FlowJo version 9.0 (Tree Star). Cell sorting was performed using FACSAria or MoFlo.
Clinical analysis
Peripheral blood was collected from healthy donors (n = 27) or patients (day 60 after BMT) of an observational study (n = 18) and a phase 3 clinical trial (ACTRN12614000266662) (n = 25). All studies were approved by the institutional ethics committee, and all patients signed informed consent. Peripheral blood mononuclear cells were purified from whole blood using Ficoll-Paque centrifugation and stained immediately.
Gene expression analysis
Total RNA was extracted with the RNeasy Micro Kit (Qiagen), and gene expression was determined using TaqMan GE assays (Applied Biosystems). All measurements were run in parallel with the housekeeping gene Hprt. All primer/probe mixtures were purchased from Applied Biosystems.
Statistics
Results from mouse experiments are presented as means ± SEM, and the Mann-Whitney U test was used for comparisons. Results from clinical samples are presented as median ± interquartile range, and Mann-Whitney U test was used for comparisons. Survival is estimated and plotted using Kaplan-Meier methods, and the difference between subgroups is estimated using log-rank methods. Ordinary least-squares method is used in the linear or semi-log regression analysis. A two-sided P value of 0.05 is considered statistically significant. Statistical analyses are performed using Prism version 6 software (GraphPad) (NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.)
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